公开(公告)号：US10761087B2

公开(公告)日：2020-09-01

申请号：US16063047

申请日：2016-12-16

Applicant: Link Genomics, Inc. ,  ROHTO Pharmaceutical Co., Ltd.

Inventor： Shinichiro Niwa ,  Dai Ogura ,  Hidemi Mizunuma ,  Yoko Arai ,  Takahiro Kurose ,  Yoshihiro Takai ,  Yoko Mitsuguchi ,  Mariyo Moriya

IPC: G01N33/50 ,  A61K31/436 ,  A61K31/192 ,  A61K31/38 ,  A61K31/404 ,  A61K31/421 ,  A61K31/426 ,  A61K31/47 ,  A61K31/41 ,  A61K45/00 ,  A61P27/02 ,  A61K45/06

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

公开(公告)号：US20220280515A1

公开(公告)日：2022-09-08

申请号：US17632419

申请日：2020-08-06

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Yoshihiro Takai ,  Takahiro Kurose

IPC: A61K31/519 ,  A61P27/04

Abstract: The present invention relates to an ophthalmic composition for promoting tear secretion, the composition comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile or a salt thereof.

公开(公告)号：US20180364216A1

公开(公告)日：2018-12-20

申请号：US16063047

申请日：2016-12-16

Applicant: Link Genomics, Inc. ,  ROHTO Pharmaceutical Co., Ltd.

Inventor： Shinichiro Niwa ,  Dai Ogura ,  Hidemi Mizunuma ,  Yoko Arai ,  Takahiro Kurose ,  Yoshihiro Takai ,  Yoko Mitsuguchi ,  Mariyo Moriya

IPC: G01N33/50 ,  A61K31/192 ,  A61K31/404 ,  A61K31/38 ,  A61K31/421 ,  A61K31/426 ,  A61K31/436 ,  A61P27/02

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

公开(公告)号：US20150064281A1

公开(公告)日：2015-03-05

申请号：US14391559

申请日：2013-04-04

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kazuhiro Fukushima ,  Mariyo Kato ,  Yoshihiro Takai ,  Masashi Itoh

IPC: A61K31/155 ,  A61K33/30

CPC classification number: A61K31/155 ,  A61K31/785 ,  A61K33/22 ,  A61K33/30 ,  A61L12/142 ,  A61K2300/00

Abstract: The present invention provides an ophthalmic composition containing (A) a biguanide-based disinfectant and (B) zinc chloride. According to the present invention, an ophthalmic composition having remarkably increased disinfection effects against Acanthamoeba is provided.

Abstract translation: 本发明提供含有（A）双胍类消毒剂和（B）氯化锌的眼用组合物。 根据本发明，提供了对棘阿米巴具有显着提高的消毒效果的眼用组合物。

公开(公告)号：US09724312B2

公开(公告)日：2017-08-08

申请号：US14154688

申请日：2014-01-14

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Takahiro Kurose ,  Takayuki Miyano ,  Mariyo Kato ,  Yoshihiro Takai

IPC: A61K31/121 ,  A61K47/02 ,  A61K45/06 ,  A61K9/00 ,  A61K47/26 ,  A61K47/44

CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K9/0053 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.